{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:17:43Z","timestamp":1782987463905,"version":"3.54.5"},"reference-count":130,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.hoc.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T14:03:18Z","timestamp":1669212198000},"page":"51-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Surgical Management of the Axilla for Breast Cancer"],"prefix":"10.1016","volume":"37","author":[{"given":"Alison","family":"Laws","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/tbj.13729","article-title":"The evolution of sentinel node biopsy for breast cancer: Personal experience","volume":"26","author":"Giuliano","year":"2020","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(19800701)46:1<1::AID-CNCR2820460102>3.0.CO;2-3","article-title":"Findings from NSA BP\u2217 Protocol No. B-04-Comparison of Radical Mastectomy with Alternative Treatments for Primary Breast Cancer 1. Radiation Compliance and its Relation to Treatment Outcome","volume":"46","author":"Fisher","year":"1980","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib4","first-page":"161","article-title":"Ipsilaterial breast tumor recurrence and survival following lumpectomy and irradiation: Pathological findings from NSABP protocol B-06","volume":"8","author":"Fisher","year":"1992","journal-title":"Semin Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.suc.2012.12.007","article-title":"Landmark trials affecting the surgical management of invasive breast cancer","volume":"93","author":"Black","year":"2013","journal-title":"Surg Clin North Am"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","article-title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","volume":"8","author":"Krag","year":"2007","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2022.08.005_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(06)70947-0","article-title":"Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study","volume":"7","author":"Veronesi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21535","article-title":"Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection","volume":"102","author":"Ashikaga","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2022.08.005_bib10","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.2010.28.2491","article-title":"Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32","volume":"28","author":"Land","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-005-9025-7","article-title":"Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer","volume":"95","author":"Fleissig","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A\u00a0Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/SLA.0b013e3181c0e92a","article-title":"Sentinel lymph node biopsy in breast cancer: Ten-year results: Of a randomized controlled study","volume":"251","author":"Veronesi","year":"2010","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/annonc\/mdn746","article-title":"Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial","volume":"20","author":"Canavese","year":"2009","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2011.1034","article-title":"Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer","volume":"306","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib17","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","article-title":"Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000","volume":"20","author":"Sol\u00e1","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2022.08.005_bib19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/bjs\/znab141","article-title":"Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial","volume":"108","author":"Andersson","year":"2021","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA - J Am Med Assoc"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ejso.2016.12.011","article-title":"Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial","volume":"43","author":"S\u00e1volt","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2019.03.002","article-title":"Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice","volume":"45","author":"Garcia-Etienne","year":"2019","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/SLA.0000000000002440","article-title":"Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era","volume":"268","author":"Poodt","year":"2018","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.hoc.2022.08.005_bib26","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1245\/s10434-020-09533-z","article-title":"Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers","volume":"28","author":"Kantor","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jamcollsurg.2015.02.035","article-title":"Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer","volume":"221","author":"Yao","year":"2015","journal-title":"J\u00a0Am Coll Surg"},{"issue":"32","key":"10.1016\/j.hoc.2022.08.005_bib28","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2014.56.5838","article-title":"Radiation field design in the ACOSOG Z0011 (Alliance) Trial","volume":"32","author":"Jagsi","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib29","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1245\/s10434-021-10441-z","article-title":"A\u00a0National Survey of Breast Surgeons and Radiation Oncologists on Contemporary Axillary Management in Mastectomy Patients","volume":"28","author":"Cortina","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3361-y","article-title":"Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: The randomized controlled SENOMAC trial","volume":"17","author":"de Boniface","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2022.08.005_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.breast.2016.06.016","article-title":"SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes","volume":"30","author":"Tinterri","year":"2016","journal-title":"Breast"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054365","volume":"11","author":"Goyal","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41523-021-00336-3","article-title":"Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial","volume":"7","author":"Houvenaeghel","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2020.04.042","article-title":"Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial","volume":"107","author":"Hildebrandt","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4_Supplement","key":"10.1016\/j.hoc.2022.08.005_bib35","doi-asserted-by":"crossref","first-page":"PD4-01","DOI":"10.1158\/1538-7445.SABCS20-PD4-01","article-title":"Abstract PD4-01: Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes : A multicenter randomized clinical trial. Sinodar One","volume":"81","author":"Tinterri","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jso.20373","article-title":"The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance","volume":"92","author":"Leidenius","year":"2005","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/SLA.0b013e31827660a8","article-title":"Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial","volume":"256","author":"Martelli","year":"2012","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2005.01.5784","article-title":"Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93","volume":"24","author":"Rudenstam","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2022.08.005_bib39","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2012.45.2615","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343","volume":"31","author":"Hughes","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3443-x","article-title":"Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)","volume":"17","author":"van Roozendaal","year":"2017","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2022.08.005_bib42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ejso.2016.01.020","article-title":"Physical function of the upper limb after breast cancer surgery. Results from the SOUND (Sentinel node vs. Observation after axillary Ultra-souND) trial","volume":"42","author":"Gentilini","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4048\/jbc.2021.24.e47","article-title":"Imaging Protocol and Criteria for Evaluation of Axillary Lymph Nodes in the NAUTILUS Trial","volume":"24","author":"Chang","year":"2021","journal-title":"J\u00a0Breast Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jso.20010","article-title":"Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study","volume":"85","author":"Aihara","year":"2004","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib45","first-page":"18","article-title":"Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: Initially node negative and node positive converted to node negative - A systemic review and meta-analysis","volume":"24","author":"Shirzadi","year":"2019","journal-title":"J\u00a0Res Med Sci"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib46","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1245\/s10434-020-09073-6","article-title":"Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer","volume":"28","author":"Kantor","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib47","first-page":"249","article-title":"Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic","volume":"188","author":"Un Park","year":"2021"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07757-6","article-title":"The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making","volume":"21","author":"Whitehead","year":"2021","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.hoc.2022.08.005_bib49","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1245\/s10434-019-07785-y","article-title":"Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach","volume":"26","author":"Weiss","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib50","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1245\/s10434-017-6016-y","article-title":"The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype","volume":"24","author":"Pilewskie","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2022.08.005_bib51","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2022.08.005_bib52","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1200\/JCO.2006.08.8013","article-title":"Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation","volume":"25","author":"Bevilacqua","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cncr.10229","article-title":"Predictive model of axillary lymph node involvement in women with small invasive breast carcinoma: Axillary metastases in breast carcinoma","volume":"94","author":"Martin","year":"2002","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2022.08.005_bib54","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1530::AID-CNCR14>3.0.CO;2-U","article-title":"Axillary lymph node metastases associated with small invasive breast carcinomas","volume":"85","author":"Maibenco","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib55","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10257","key":"10.1016\/j.hoc.2022.08.005_bib56","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2022.08.005_bib58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2022.08.005_bib59","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2022.08.005_bib60","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2214\/AJR.05.0936","article-title":"Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review","volume":"186","author":"Alvarez","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/SLA.0b013e31821f1564","article-title":"Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla","volume":"254","author":"Houssami","year":"2011","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jso.21911","article-title":"The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis","volume":"104","author":"Tan","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","article-title":"Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study","volume":"173","author":"Classe","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients","volume":"250","author":"Hunt","year":"2009","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.hoc.2022.08.005_bib65","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ejca.2015.03.014","article-title":"Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment","volume":"51","author":"van der Heiden-Van Der Loo","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2022.08.005_bib66","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clbc.2017.05.002","article-title":"Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy","volume":"17","author":"Nogi","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib67","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2022.08.005_bib68","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2022.08.005_bib69","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.ejso.2017.07.023","article-title":"Sentinel node biopsy after primary chemotherapy in cT2 N0\/1 breast cancer patients: Long-term results of a retrospective study","volume":"43","author":"Martelli","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2022.08.005_bib70","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib71","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1245\/s10434-018-6578-3","article-title":"Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy","volume":"25","author":"Barron","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.radonc.2021.08.013","article-title":"Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy","volume":"163","author":"Leonardi","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-017-4164-1","article-title":"Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer","volume":"163","author":"Zetterlund","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.hoc.2022.08.005_bib74","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clbc.2017.03.014","article-title":"Predictive Factors for Nonsentinel Lymph Node Metastasis in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy: Nomogram for Predicting Nonsentinel Lymph Node Metastasis","volume":"17","author":"Ryu","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib75","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib76","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cncr.23481","article-title":"Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy","volume":"112","author":"Jeruss","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2022.08.005_bib77","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1245\/s10434-021-09910-2","article-title":"Is Residual Nodal Disease at Axillary Dissection Associated with Tumor Subtype in Patients with Low Volume Sentinel Node Metastasis After Neoadjuvant Chemotherapy?","volume":"28","author":"Moo","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000489565","article-title":"Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy","volume":"13","author":"Liedtke","year":"2018","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib79","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib80","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"issue":"11","key":"10.1016\/j.hoc.2022.08.005_bib81","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1245\/s10434-021-09897-w","article-title":"Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)","volume":"28","author":"Weiss","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib82","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.2214\/AJR.17.18323","article-title":"MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial","volume":"210","author":"Scheel","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib83","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.27995","article-title":"Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017","volume":"119","author":"de Los Santos","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib84","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.4103","article-title":"Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer","volume":"155","author":"Tasoulis","year":"2020","journal-title":"JAMA Surg"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib85","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1245\/s10434-020-09273-0","article-title":"Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study","volume":"28","author":"van Loevezijn","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/bjs.12026","article-title":"Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer","volume":"108","author":"van der Noordaa","year":"2021","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib90","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1245\/s10434-015-4944-y","article-title":"Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?","volume":"23","author":"Pilewskie","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib91","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1245\/s10434-017-5935-y","article-title":"Positive Ultrasound-guided Lymph Node Needle Biopsy in Breast Cancer may not Mandate Axillary Lymph Node Dissection","volume":"24","author":"Harris","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2022.08.005_bib92","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ejso.2018.04.003","article-title":"Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result","volume":"44","author":"Lim","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib93","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12094-019-02162-3","article-title":"Evaluation of axillary lymph node metastasis burden by preoperative ultrasound in early-stage breast cancer with needle biopsy-proven metastasis","volume":"22","author":"Wang","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib94","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-020-05636-z","article-title":"Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis","volume":"181","author":"Yoo","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.hoc.2022.08.005_bib95","author":"Rashmi Kumar"},{"issue":"27","key":"10.1016\/j.hoc.2022.08.005_bib96","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline","volume":"39","author":"Brackstone","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","article-title":"Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"60","author":"Weber","year":"2021","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.hoc.2022.08.005_bib98","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.ejso.2021.04.041","article-title":"Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients","volume":"47","author":"Schipper","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib99","article-title":"Surgical management of axilla following neoadjuvant endocrine therapy","author":"Murphy","year":"2021","journal-title":"Ann Surg Ancol"},{"key":"10.1016\/j.hoc.2022.08.005_bib100","article-title":"Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes","author":"Friedman-Eldar","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-00177-6","article-title":"Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer","volume":"6","author":"Kantor","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib102","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"14","key":"10.1016\/j.hoc.2022.08.005_bib103","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.hoc.2022.08.005_bib104","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib105","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance)","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib106","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib107","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/XCS.0000000000000098","article-title":"Prospective Evaluation of Radar-Localized Reflector-Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy","volume":"234","author":"Gallagher","year":"2022","journal-title":"J\u00a0Am Coll Surg"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib108","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2022.08.005_bib109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clbc.2017.04.006","volume":"17","author":"van Nijnatten","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"4_Supplement","key":"10.1016\/j.hoc.2022.08.005_bib110","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1538-7445.SABCS20-GS1-10","article-title":"Abstract GS1-10: Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial","volume":"81","author":"Simons","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib111","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00404-019-05428-x","article-title":"Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature","volume":"301","author":"Banys-Paluchowski","year":"2020","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"10.1016\/j.hoc.2022.08.005_bib112","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1245\/s10434-019-07419-3","article-title":"Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node","volume":"26","author":"Patel","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib113","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-022-06588-2","article-title":"False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy","author":"de Boniface","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib114","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ejso.2019.11.501","article-title":"Ultrasound guided tattooing of axillary lymph nodes in breast cancer patients prior to neoadjuvant therapy, and identification of tattooed nodes at the time of surgery","volume":"46","author":"Allweis","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2022.08.005_bib115","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1245\/s10434-015-4527-y","article-title":"Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes","volume":"22","author":"Plecha","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib116","article-title":"A\u00a0Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-Positive Breast Cancer Patients","author":"Kuemmel","year":"2020","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.hoc.2022.08.005_bib117","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1245\/s10434-018-6548-9","article-title":"Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis","volume":"25","author":"Wu","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib118","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/j.clbc.2020.08.001","article-title":"Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization","volume":"21","author":"Sun","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib119","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2214\/AJR.19.21378","article-title":"Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment","volume":"213","author":"Greenwood","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.hoc.2022.08.005_bib120","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1245\/s10434-020-09542-y","article-title":"Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients","volume":"28","author":"Simons","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib121","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1245\/s10434-020-08902-y","article-title":"Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers","volume":"27","author":"Laws","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2022.08.005_bib122","doi-asserted-by":"crossref","DOI":"10.1007\/s12282-022-01349-x","article-title":"Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients","author":"Pinto","year":"2022","journal-title":"Breast Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2022.08.005_bib123","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib124","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2022.08.005_bib125","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2022.08.005_bib126","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4048\/jbc.2018.21.e54","article-title":"Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis","volume":"21","author":"Choi","year":"2018","journal-title":"J\u00a0Breast Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2022.08.005_bib127","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10549-017-4423-1","article-title":"Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy","volume":"166","author":"Kang","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.hoc.2022.08.005_bib128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4048\/jbc.2021.24.e48","article-title":"Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy","volume":"24","author":"Kim","year":"2021","journal-title":"J\u00a0Breast Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2022.08.005_bib129","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.ejso.2021.06.024","article-title":"Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study","volume":"47","author":"Cab\u0131o\u011flu","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","article-title":"Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol","volume":"193","author":"van Loevezijn","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.hoc.2022.08.005_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071565","article-title":"Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study","volume":"13","author":"Banys-paluchowski","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.hoc.2022.08.005_bib132","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clbc.2021.07.011","article-title":"MINImal vs. MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer: Protocol of a Dutch Multicenter Registry Study (MINIMAX)","volume":"22","author":"de Wild","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.hoc.2022.08.005_bib134","article-title":"NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy","volume":"17","author":"Tinterri","year":"2019","journal-title":"Contemp Clin Trials Commun"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858822000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:18:30Z","timestamp":1760185110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858822000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0889858822000892"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2022.08.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical Management of the Axilla for Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}